ArticleFrontiers in endocrinology2022

Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis.

Tongtong Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.